

Haematologica
HAEMATOL/2016/145763
Version 2

The optimal dosing of Gemtuzumab Ozagamicine: where to go?

Theo de Witte and Sergio Amadori

Disclosures: Both authors have collaborated with Wyeth and coordinated clinical trials through their clinical trials groups with the EORTC and GIMEMA. The educational support was allocated to the group institutions rather than to their own institutions.

Contributions: Both authors have contributed to the conception and writing of the manuscript.